ArticleScience translational medicine2021
Genetic analysis of praziquantel response in schistosome parasites implicates a transient receptor potential channel.
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Direct measurement ofbioRxiv : the preprint server for biology · 2026Article
- Extensive parasite transmission and variation in a functional receptor associated with drug resistance in endemicScience advances · 2026Article
- Strevertene A, a Streptomyces-Derived Macrolide, Reveals Selective Activity against the Human ParasiteACS omega · 2026Article
- Plant-Derived Terpenes as Emerging Therapeutics Against Schistosomiasis.International journal of molecular sciences · 2026Review
- Use of a cytochrome P450 humanized mouse model to refine schistosomiasis drug discovery.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- TRPtracker: a community database for monitoring praziquantel sensitivity at TRPMInternational journal for parasitology. Drugs and drug resistance · 2026Article
- Resistance evaluation and surveillance initiative for schistosomiasis treatment: study protocol for the RESIST project.BMC infectious diseases · 2026Article
- Loss of vitamin C biosynthesis protects from the pathology of a parasitic infection.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Enrichment of Helminth Mitochondrial Genomes From Faecal Samples Using Hybridisation Capture.Molecular ecology resources · 2025Article
- Mechanisms underlying persistent liver fibrosis progression in Schistosoma-infected individuals post-treatment.Infectious diseases of poverty · 2025Article
- Development of a Novel Compound Effective Against Juvenile, Adult, and Drug-ResistantPharmaceutics · 2025Review
- TRPtracker: a community database for monitoring praziquantel sensitivity at TRPMbioRxiv : the preprint server for biology · 2025Article
- Abundant genetic variation is retained in many laboratory schistosome populations.PLoS pathogens · 2025Article
- Pooled, Long-read Sequencing for Structural Variant Characterization in Schistosome Populations.Genome biology and evolution · 2025Article
- The research contribution of the Schistosomiasis Collection at the Natural History Museum (SCAN): highlights, challenges and future directions.Infectious diseases of poverty · 2025Review
- Transcriptional phenotype of the anti-parasitic benzodiazepine meclonazepam on the blood fluke Schistosoma mansoni.PLoS neglected tropical diseases · 2025Article
- A genome-scale drug discovery pipeline uncovers new therapeutic targets and a unique p97 allosteric binding site inbioRxiv : the preprint server for biology · 2025Article
- Antischistosomal Potential of Animal-Derived Natural Products and Compounds.Microorganisms · 2025Review
- A comparative parasitological, histopathological, and proteomic analysis ofFrontiers in veterinary science · 2025Article
Corrections and comments
- Commented on by
Authors and funding
22 authors.
Funding
Abstract
Mass drug administration with praziquantel (PZQ) monotherapy is considered the mainstay for control and elimination of the parasites causing schistosomiasis in humans. This drug shows imperfect cure rates in the field, and parasites showing reduced PZQ response can be selected in the laboratory, but the extent of resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.